Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

CagriSema led to a 20.4% weight loss at 68 weeks vs. 3.0% with placebo in adults without diabetes. 50.7% of CagriSema users with obesity reached a BMI under 30, compared to 10.2% in the placebo ...

CagriSema is not approved in the US for weight loss. About the REDEFINE clinical trial program REDEFINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in obesity.

Despite hitting its primary endpoints, patients on CagriSema achieved a weight loss of 22.7% compared to a reduction of 16.1% with semaglutide or 11.8% with cagrilintide after 68 weeks.

Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy. Here’s what we know so far about this promising new option for.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss.